{
    "clinical_study": {
        "@rank": "151456", 
        "arm_group": [
            {
                "arm_group_label": "Anemia", 
                "arm_group_type": "Active Comparator", 
                "description": "Hb < 120 g/L in women, Hb < 130 g/L in men Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid"
            }, 
            {
                "arm_group_label": "Iron deficiency", 
                "arm_group_type": "Active Comparator", 
                "description": "ferritin < 100 \u00b5g/l Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid"
            }, 
            {
                "arm_group_label": "Natural comparison group", 
                "arm_group_type": "No Intervention", 
                "description": "Patients without anemia or iron deficiency will be observed and the same postoperative measurements performed"
            }
        ], 
        "brief_summary": {
            "textblock": "We are performing the above prospective randomized trial in 1'000 patients undergoing\n      cardiac surgery. The study will answer the question of whether preoperative treatment of\n      anemia or iron deficiency indeed improves transfusion needs (primary outcome) and important\n      clinical outcomes (secondary outcome) in a large group of cardiac surgical patients. The\n      list of inclusion and exclusion criteria was deliberately chosen short so that this patient\n      group largely reflects today's clinical practice .\n\n        -  Trial with medical product"
        }, 
        "brief_title": "Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anemia", 
            "Iron Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Anemic or iron deficiency patients are randomized  into treatment and placebo groups.\n      Treatment (see below) will be given the day before the operation (day -1) or a maximum of 2\n      days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days\n      prior to the operation in anemic patients (day -3). The treatment will not be disclosed to\n      the patient or the health care workers treating the patients during and after the operation.\n\n      Patients without anemia or iron deficiency will also be observed and the same postoperative\n      measurements performed. They will serve as a natural comparison group.\n\n      Treatment:\n\n      Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose\n      (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml sodiumchloride (NaCl)\n      over 30 min.\n\n      Vitamin B12 (Vitarubin\u00ae-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum\n      folicum, Streuli Pharma AG, Uznach) 5 mg po.\n\n      The current transfusion and coagulation guidelines of the University Hospital of Zurich are\n      followed in both groups identically. Postoperatively on the regular ward a Hb transfusion\n      trigger of 80 g/L is applied"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients undergoing valve- and/or coronary bypass surgery\n\n          -  Signed patient informed consent\n\n          -  Only patients will be enrolled who won't have an emergency surgery on the same day\n\n        Exclusion criteria:\n\n          -  Participation in another clinical trial within the last 4 weeks prior to enrollment\n\n          -  Addiction or other disease that did not allow the patient to assess the nature, scope\n             and possible consequences of the clinical tial\n\n          -  Patients who do not sign the consent form or may not fully understand from inadequate\n             knowledge of German.\n\n          -  Patients who have not reached the age of legal majority\n\n          -  Pregnant or lactating women\n\n          -  Jehovah's Witnesses\n\n          -  Patients with endocarditis\n\n          -  Existing allergy or intolerance to ferric carboxymaltose or mannitol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031289", 
            "org_study_id": "IFA2012/IDCS"
        }, 
        "intervention": {
            "arm_group_label": [
                "Anemia", 
                "Iron deficiency"
            ], 
            "description": "Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).\nErythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.\nVitamin B12 (Vitarubin\u00ae-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po.", 
            "intervention_name": "Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid", 
            "intervention_type": "Drug", 
            "other_name": [
                "Eprex", 
                "Ferinject", 
                "Vitarubin\u00ae-superconc", 
                "Acidum folicum"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epoetin Alfa", 
                "Folic Acid", 
                "Hydroxocobalamin", 
                "Ferric Compounds", 
                "Vitamin B Complex", 
                "Vitamin B 12", 
                "Iron", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anemia", 
            "Iron deficiency", 
            "Cardiac surgery", 
            "Perioperative Care"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Institute of Anaesthesiology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "3", 
        "official_title": "Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.", 
        "overall_contact": {
            "email": "felix.schoenrath@usz.ch", 
            "last_name": "Felix Schoenrath, MD"
        }, 
        "overall_contact_backup": {
            "email": "donat.spahn@usz.ch", 
            "last_name": "Donat R Spahn, Prof MD"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Institute of Anaesthesiology", 
            "last_name": "Donat R Spahn, Prof MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Red blood cell (RBC) units transfused", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031289"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients without any RBC transfusions", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Combined allogeneic transfusions (RBC, FFP( fresh frozen plasma), platelets)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Length of stay in the intensive care unit (ICU)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Duration of mechanical ventilation", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "RIFLE I, AKIN 2", 
                "measure": "Acute kidney failure", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Myocardial infarction, stroke, death", 
                "measure": "Major Adverse Cardiac and Cerebrovascular Events (MACCE)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "New atrial fibrillation", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Pneumonia, hospital acquired Deep Sternal Wound Infection\nDefinition of infection: rise in inflammation markers after the initial postoperative period (acute phase reaction) and requires treatment and/ or prolongs days in hospital and/or microbiological confirmation of infection", 
                "measure": "Infections", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "clinical symptoms and evidence of thrombosis/ embolism in one of the following imaging methods (ultrasound, CT-scan)", 
                "measure": "Thrombotic and thromboembolic complications (90 days)", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Length of stay (LOS) in the hospital", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Length of hospital stay (in comparison to median LOS published for relevant Swiss-DRGs)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "In hospital mortality", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "30 day and 90-day mortality", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Comparison of costs for study medication versus costs for blood products and products related to transfusion", 
                "measure": "Costs (for blood products and pharmaceutical products related to transfusion and anemia management)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Perioperative Hb concentrations", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Calculated RBC and blood loss", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Comparison of the treatment and placebo groups with the natural comparison group", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Comparison of all serious adverse events between study drug group and placebo group", 
                "measure": "Safety and tolerance of administered study drug and placebo", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}